Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials
Furio Colivicchi,1 Catarina Sternhufvud,2 Sanjay K Gandhi3 1Cardiology Division, Emergency Department, San Filippo Neri Hospital, ASL Roma E, Rome, Italy; 2Global Payer Evidence and Pricing, AstraZeneca R&D, Mölndal, Sweden; 3Global Health Economics and Outcomes Research, TEVA Pharm...
Main Authors: | Colivicchi F, Sternhufvud C, Gandhi SK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-11-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | https://www.dovepress.com/impact-of-treatment-with-rosuvastatin-and-atorvastatin-on-cardiovascul-peer-reviewed-article-CEOR |
Similar Items
-
Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
by: Gandhi SK, et al.
Published: (2012-01-01) -
The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model
by: van Herick A, et al.
Published: (2012-11-01) -
Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
by: Masadeh Majed, et al.
Published: (2012-05-01) -
Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
by: García Hugo, et al.
Published: (2006-12-01) -
THE INFLUENCE OF ATORVASTATIN AND ROSUVASTATIN IN ATHEROSCLEROSIS ON THE PARAMETERS OF CELLULAR IMMUNITY AND IN VITRO LEUCOCYTE ACTIVATION
by: A. Yu. Filatova, et al.
Published: (2018-09-01)